We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBC icon
1
Invesco DB Commodity Index Tracking Fund
DBC
$1.67B
$30.6M 8.45%
1,057,238
– –
ABVX
2
Abivax
ABVX
$11.9B
$12.6M 3.48%
113,254
+41,069
+57% +$4.86M
PRAX icon
3
Praxis Precision Medicines
PRAX
$8.77B
$8.48M 2.34%
26,323
+482
+2% +$149K
COGT icon
4
Cogent Biosciences
COGT
$6.68B
$7.58M 2.09%
197,051
-139,616
-41% -$5.16M
SYRE icon
5
Spyre Therapeutics
SYRE
$8.7B
$7.38M 2.04%
146,264
-41,942
-22% -$1.58M
PCVX icon
6
Vaxcyte
PCVX
$8.12B
$7.24M 2%
124,647
+10,598
+9% +$575K
RVMD icon
7
Revolution Medicines
RVMD
$39.6B
$6.74M 1.86%
69,309
-50,931
-42% -$5.14M
TERN
8
DELISTED
Terns Pharmaceuticals
TERN
$6.03M 1.66%
114,307
-61,155
-35% -$2.51M
GPCR icon
9
Structure Therapeutics
GPCR
$3.45B
$5.97M 1.65%
123,909
-69,092
-36% -$4.73M
NUVL icon
10
Nuvalent
NUVL
$5.8M 1.6%
56,602
-16,685
-23% -$1.7M
IMVT icon
11
Immunovant
IMVT
$8.27B
$5.59M 1.54%
225,139
+3,256
+1% +$84.3K
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
$5.53M 1.53%
165,227
+30,158
+22% +$1.18M
TYRA icon
13
Tyra Biosciences
TYRA
$1.91B
$5.03M 1.39%
131,304
+96,218
+274% +$3.11M
AMLX icon
14
Amylyx Pharmaceuticals
AMLX
$1.97B
$4.89M 1.35%
352,085
+113,273
+47% +$1.59M
AMZN icon
15
Amazon
AMZN
$2.66T
$4.66M 1.29%
22,397
+5,000
+29% +$1.1M
LBRX
16
LB Pharmaceuticals
LBRX
$901M
$4.28M 1.18%
173,595
+33,488
+24% +$772K
RLAY icon
17
Relay Therapeutics
RLAY
$4.34B
$4.2M 1.16%
421,881
-123,198
-23% -$1.1M
INSM icon
18
Insmed
INSM
$23.5B
$3.98M 1.1%
24,316
-15,084
-38% -$2.32M
NVDA icon
19
NVIDIA
NVDA
$4.91T
$3.91M 1.08%
22,420
+8,200
+58% +$1.5M
ORKA
20
Oruka Therapeutics
ORKA
$5.59B
$3.87M 1.07%
+78,911
New +$2.74M
CYTK icon
21
Cytokinetics
CYTK
$10.9B
$3.87M 1.07%
58,643
-55,921
-49% -$3.55M
LQDA icon
22
Liquidia Corp
LQDA
$7.11B
$3.76M 1.04%
99,744
-56,259
-36% -$2.09M
OCUL icon
23
Ocular Therapeutix
OCUL
$1.96B
$3.74M 1.03%
441,573
+97,506
+28% +$929K
TARS icon
24
Tarsus Pharmaceuticals
TARS
$2.61B
$3.68M 1.02%
52,464
-1,100
-2% -$76.9K
BBIO icon
25
BridgeBio Pharma
BBIO
$15.9B
$3.68M 1.02%
49,560
-30,645
-38% -$2.22M
1
2 3 4 5

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.